Breaking Down Shandong Shanda Wit Science and Technology Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) is a hidden gem or a turnaround story? This deep-dive unpacks the numbers: Q3 revenue surged to 432.12 million CNY - a striking 93.28% year-over-year jump - with TTM revenue at 2.36 billion CNY after a 2024 annual dip to 2.13 billion CNY; profitability is eye-catching too, featuring a 24.16% net profit margin and 26.03% ROE, backed by TTM EPS of 2.38 CNY and a 7.34% dividend yield (2.50 CNY per share); balance-sheet strength shows a debt-to-equity of 0%, EV/EBITDA of 4.90, current and quick ratios of 7.12 and 6.79 respectively, and cash dynamics including a -226.27 million CNY net change in the latest quarter - all set against valuation signals (market cap 7.74 billion CNY, P/E ≈14, P/S ~3.4, implied fair price 79.61 CNY with 141.1% upside) and growth forecasts (earnings +6.6% p.a., revenue +4.8% p.a., EPS +6.5% p.a.); if you want the full risk-vs.-reward picture - regulatory, competitive and supply-chain exposures included - keep reading.

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Revenue Analysis

• Quarter (Q3 2025) revenue: 432.12 million CNY (+93.28% YoY)
• TTM revenue: 2.36 billion CNY (+10.06% YoY)
• 2024 full-year revenue: 2.13 billion CNY (-14.08% vs. 2023)
• Workforce: 1,759 employees; revenue per employee ≈ 1.34 million CNY
• Market cap: 7.74 billion CNY; P/S ratio: 3.47

• Recent quarter's sharp revenue acceleration suggests momentum that may reverse the 2024 decline if sustained across remaining quarters.
• TTM growth (10.06%) indicates recovery at scale but still requires confirmation through subsequent quarters and margin trends.
• P/S of 3.47 positions valuation relative to revenue growth-investors should compare to peers and margin profiles.

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Profitability Metrics

Key profitability indicators for Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) show a combination of strong margins, high shareholder returns, and income-generating capacity that may attract income-focused and value-oriented investors.

• TTM EPS: 2.38 CNY; current P/E: 13.86 - implies earnings support the current share price.
• Net profit margin: 24.16% - indicates efficient conversion of revenue into profit.
• ROE: 26.03% - strong return on shareholders' equity.
• Dividend: 2.50 CNY per share annually; dividend yield: 7.34% - attractive cash return for investors.
• EBITDA: 1.18 billion CNY - signals robust operating cash-generation before non-cash and financing items.
• P/E (13.86) is below the industry median - potential undervaluation relative to peers.

Investor-relevant implications can be summarized as:

• Strong EPS and ROE support sustainable shareholder returns if earnings persist.
• High net margin and sizable EBITDA indicate operational efficiency and earnings quality.
• The 7.34% yield and 2.50 CNY dividend make the stock attractive for income strategies, but dividend sustainability should be monitored against cash flow and capex.
• A P/E below the industry median points to potential undervaluation - warrants relative-valuation and growth-rate checks versus peers.

Further company context and investor activity can be found here: Exploring Shandong Shanda Wit Science and Technology Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Debt vs. Equity Structure

• Debt-to-Equity Ratio: 0% - no reliance on debt financing.
• Return on Invested Capital (ROIC): 17.98% - effective use of capital.
• Enterprise Value (EV): 6.20 billion CNY with EV/EBITDA = 4.90 - valuation appears reasonable relative to operating earnings.
• Current Ratio: 7.12 - strong short-term solvency.
• Quick Ratio: 6.79 - sufficient immediate liquidity to cover obligations without inventory reliance.
• Investor appeal: conservative debt approach may attract risk-averse investors.

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Liquidity and Solvency

• Current ratio: 7.12 - ample coverage of short-term liabilities by current assets.
• Quick ratio: 6.79 - high immediate liquidity excluding inventories.
• Net change in cash (latest quarter): -226.27 million CNY - quarter showed cash outflows exceeding inflows.
• Total assets: 4.78 billion CNY; Total liabilities: 473.75 million CNY - low leverage and strong asset base.
• Effective tax rate: 13.86% - aligned with typical industry levels.
• Conservative debt posture - limited borrowing reduces solvency risk and appeals to risk‑averse investors.

• Investor implications: strong liquidity cushions operational needs and supports short‑term obligations despite the recent negative cash flow quarter.
• Risk considerations: continued negative cash flow trends would merit monitoring; low debt reduces default risk but may limit leverage-driven growth.

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Valuation Analysis

• Trailing P/E: 14.14 - reflects recent 12-month earnings.
• Forward P/E: 14.16 - market expectations show earnings stability year-over-year.
• P/S (company-reported): 3.35; P/S (market-cap derived): 3.47 - revenue multiples in a reasonable band for the sector.
• P/B: 1.88 - indicates the stock trades below 2x book value.
• Enterprise Value (EV): 6.20 billion CNY; EV/EBITDA: 4.90 - suggests relatively low operating cash-flow multiple.
• Market Capitalization: 7.74 billion CNY.
• Relative fair price estimate: 79.61 CNY per share, implied upside: 141.1% vs. current market price.
• Valuation positioning: competitive within the pharmaceutical industry, supported by the above multiples.

• Interpretation: P/E in the mid-teens combined with sub-5 EV/EBITDA signals a valuation that may be attractive for value-oriented investors in pharmaceutical/biotech sectors.
• Risks to watch: execution on revenue growth, margin trends that would affect forward P/E, and industry-specific regulatory or R&D-related events that could compress multiples.

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Risk Factors

Investors evaluating Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) should weigh a set of industry-specific and company-specific risks that can materially affect revenue, margins, cash flow and valuation. Below are principal risk categories with quantified sensitivities where applicable, and practical indicators to monitor.

• Regulatory risk: frequency and scope of regulatory changes in China and export markets can alter approval timelines, product labeling, GMP compliance costs and market access.
• Competitive pressure: pricing, market share erosion and margin compression from generics, multinational pharma and biotech disruptors.
• Raw material cost volatility: active pharmaceutical ingredient (API) and excipient price moves directly affect gross margin.
• Macroeconomic downturn: weaker consumer spending and hospital budgets reduce product demand and receivable collectibility.
• Currency risk: RMB fluctuations versus USD/EUR impact reported international revenues and imported input costs.
• Operational risks: supply chain disruptions, quality-control incidents, and production delays affect sales timing and inventory write-downs.

Key observable metrics and trigger levels for risk monitoring:

Scenario sensitivity analysis (illustrative):

• Base case: stable regulation, moderate growth - revenue growth 6-10%/yr, EBITDA margin 16-20%.
• Adverse regulatory shock: approval delays + supply rework - near-term revenue decline 8-15%, incremental one-off compliance costs equal to 1-2% of annual revenue.
• Commodity-driven margin squeeze: API cost surge 20% - gross margin drop 2-4 percentage points; EBITDA falls proportionally unless offset by price increases.
• Macroeconomic stress: demand contraction 10% - working capital days rise 10-20 days, increasing financing needs and pressure on liquidity ratios.

Practical investor checklist to track ongoing risk exposure:

• Regulatory filings, public recall/inspection notices, and time-to-market changes for pipeline drugs.
• Gross margin trends and API cost disclosures in quarterly reports; supplier concentration metrics.
• Receivables aging, DSO, and cash conversion cycle to spot demand/collection deterioration.
• FX exposure disclosures and hedging policy; percentage of revenue from exports vs. imports invoiced in foreign currencies.
• Production utilization rates, disclosed downtime events, and capex for capacity or quality improvements.

For background on corporate structure, history and how the company makes money see: Shandong Shanda Wit Science and Technology Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) - Growth Opportunities

Shandong Shanda Wit Science and Technology Co., Ltd. (000915.SZ) shows measurable growth projections and strategic levers that investors should weigh when assessing future upside. Key forward-looking metrics indicate steady top-line expansion, improving profitability and shareholder returns over the next three years.

• Forecasted earnings growth: 6.6% compound annual growth rate (CAGR) in net income over the next three years.
• Revenue growth expectation: 4.8% CAGR, signaling steady demand and incremental market penetration.
• EPS trajectory: Projected EPS growth of 6.5% per annum, supporting enhanced per-share value.
• Return on equity (ROE): Anticipated to rise to 21.4% by year three, reflecting operational leverage and capital efficiency improvements.

Drivers supporting these projections include product diversification, strategic partnerships, targeted M&A and investments in R&D and production capacity:

• Diverse product portfolio enabling cross-selling and entry into adjacent markets.
• Potential strategic partnerships with domestic and overseas OEMs and tech firms to accelerate distribution and technology adoption.
• Acquisitions focused on complementary capabilities or distribution channels to amplify scale and margins.
• Ongoing cost optimization and higher-margin product mix that can lift net margins over the forecast horizon.

Specific tactical initiatives likely to affect these metrics:

• Scaling higher-margin segments within the product portfolio to lift consolidated margins.
• Leveraging partnerships to shorten product commercialization cycles and expand channels.
• Selective acquisitions to add capabilities or market share without diluting ROE.
• Investments in automation and process improvements to improve unit economics and protect margins against raw material inflation.

For context on the company's guiding principles that may underpin long-term strategy and capital allocation decisions, see: Mission Statement, Vision, & Core Values (2026) of Shandong Shanda Wit Science and Technology Co., Ltd.